[HTML][HTML] Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a …
J Guigay, C Ortholan, D Vansteene… - The Lancet Healthy …, 2024 - thelancet.com
Background At present, there is no established standard treatment for frail older patients with
recurrent or metastatic head and neck squamous cell carcinoma. We aimed to compare the …
recurrent or metastatic head and neck squamous cell carcinoma. We aimed to compare the …
Cetuximab every 2 weeks versus standard weekly dosing administration schedule
C Bokemeyer, F Ciardiello, O Dubreuil, J Guigay… - Future …, 2024 - Taylor & Francis
Cetuximab every 2 weeks (Q2W) dosing schedule is approved by the US FDA and by the
Japanese Pharmaceuticals and Medical Devices Agency in patients with metastatic …
Japanese Pharmaceuticals and Medical Devices Agency in patients with metastatic …
[HTML][HTML] Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a …
J Guigay, H Le Caer, FR Ferrand… - The Lancet Healthy …, 2024 - thelancet.com
Background A standard treatment for fit, older patients with recurrent or metastatic head and
neck squamous cell carcinoma (HNSCC) is yet to be established. In the previous EXTREME …
neck squamous cell carcinoma (HNSCC) is yet to be established. In the previous EXTREME …
[HTML][HTML] Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy
L Satgunaseelan, S Porazinski, D Strbenac… - Frontiers in …, 2021 - frontiersin.org
There is an increasing worldwide incidence of patients under 50 years of age presenting
with oral squamous cell carcinoma (OSCC). The molecular mechanisms driving disease in …
with oral squamous cell carcinoma (OSCC). The molecular mechanisms driving disease in …
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single …
M Dzienis, J Cundom, CS Fuentes… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE Standard-of-care first-line treatment for recurrent/metastatic head and neck
squamous cell carcinoma (R/M HNSCC) is pembrolizumab plus platinum and fluorouracil …
squamous cell carcinoma (R/M HNSCC) is pembrolizumab plus platinum and fluorouracil …
[HTML][HTML] Managing recurrent/advanced oropharyngeal/oesophageal cancer with cetuximab-based regimens: A case series
PS Dattatreya, SS Nirni, AV Suresh - F1000Research, 2024 - f1000research.com
Background: Several clinical trials in a setting of recurrent/metastatic (R/M) squamous cell
carcinoma of head and neck (HNSCC) have reported the use of cetuximab with …
carcinoma of head and neck (HNSCC) have reported the use of cetuximab with …